D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
ITCI holding history
Intra-Cellular Therapies, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ITCI overviewAll 13F holders of ITCIFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −923,809−100.0% | Sold out | Holders |
| Q1 2025 | 923,809 | $121.9M | 0.1% | +389,348+72.8% | Added | Holders |
| Q4 2024 | 534,461 | $44.6M | <0.1% | +165,781+45.0% | Added | Holders |
| Q3 2024 | 368,680 | $27.0M | <0.1% | −211,679−36.5% | Reduced | Holders |
| Q2 2024 | 580,359 | $39.7M | 0.1% | +190,080+48.7% | Added | Holders |
| Q1 2024 | 390,279 | $27.0M | <0.1% | −121,271−23.7% | Reduced | Holders |
| Q4 2023 | 511,550 | $36.6M | 0.1% | −229,827−31.0% | Reduced | Holders |
| Q3 2023 | 741,377 | $38.6M | 0.1% | −211,465−22.2% | Reduced | Holders |
| Q2 2023 | 952,842 | $60.3M | 0.1% | +442,938+86.9% | Added | Holders |
| Q1 2023 | 509,904 | $27.6M | <0.1% | −3,596−0.7% | Reduced | Holders |
| Q4 2022 | 513,500 | $27.2M | <0.1% | +163,422+46.7% | Added | Holders |
| Q3 2022 | 350,078 | $16.3M | <0.1% | +11,417+3.4% | Added | Holders |
| Q2 2022 | 338,661 | $19.3M | <0.1% | −25,957−7.1% | Reduced | Holders |
| Q1 2022 | 364,618 | $22.3M | <0.1% | +211,031+137.4% | Added | Holders |
| Q4 2021 | 153,587 | $8.04M | <0.1% | +153,587 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −48,063−100.0% | Sold out | Holders |
| Q2 2021 | 48,063 | $1.96M | <0.1% | −71,936−59.9% | Reduced | Holders |
| Q1 2021 | 119,999 | $4.07M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.